Global Candesartan and Hydrochlorothiazide Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Candesartan and Hydrochlorothiazide Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Candesartan and Hydrochlorothiazide contains 2 medicationscandesartan and hydrochlorothiazide. Candesartan belongs to a family of medications known as angiotensin II receptor blockers. Hydrochlorothiazide belongs to a family of medications known as diuretics (or "water pills"). This combination medication is used to lower high blood pressure.
Candesartan and Hydrochlorothiazide report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Candesartan and Hydrochlorothiazide market is projected to reach US$ 470.1 million in 2029, increasing from US$ 303 million in 2022, with the CAGR of 6.4% during the period of 2024 to 2029. Demand from Adults and Geriatric are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Candesartan and Hydrochlorothiazide industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Candesartan and Hydrochlorothiazide key manufacturers include AstraZeneca, ANI Pharmaceuticals, TEVA, Mylan, Dr. Reddy's Laboratories, Zydus Pharmaceuticals, Prinston Pharmaceutical and MACLEODS, etc. AstraZeneca, ANI Pharmaceuticals, TEVA are top 3 players and held % sales share in total in 2022.
Candesartan and Hydrochlorothiazide can be divided into 16/12.5, 32/12.5 and 32/25,, etc. 16/12.5 is the mainstream product in the market, accounting for % sales share globally in 2022.
Candesartan and Hydrochlorothiazide is widely used in various fields, such as Adults and Geriatric, etc. Adults provides greatest supports to the Candesartan and Hydrochlorothiazide industry development. In 2022, global % sales of Candesartan and Hydrochlorothiazide went into Adults filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Candesartan and Hydrochlorothiazide market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
AstraZeneca
ANI Pharmaceuticals
TEVA
Mylan
Dr. Reddy's Laboratories
Zydus Pharmaceuticals
Prinston Pharmaceutical
MACLEODS
Segment by Type
16/12.5
32/12.5
32/25
Adults
Geriatric
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Candesartan and Hydrochlorothiazide market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Candesartan and Hydrochlorothiazide, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Candesartan and Hydrochlorothiazide industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Candesartan and Hydrochlorothiazide in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Candesartan and Hydrochlorothiazide introduction, etc. Candesartan and Hydrochlorothiazide Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports Conclusions of Candesartan and Hydrochlorothiazide market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Candesartan and Hydrochlorothiazide report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Candesartan and Hydrochlorothiazide market is projected to reach US$ 470.1 million in 2029, increasing from US$ 303 million in 2022, with the CAGR of 6.4% during the period of 2024 to 2029. Demand from Adults and Geriatric are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Candesartan and Hydrochlorothiazide industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Candesartan and Hydrochlorothiazide key manufacturers include AstraZeneca, ANI Pharmaceuticals, TEVA, Mylan, Dr. Reddy's Laboratories, Zydus Pharmaceuticals, Prinston Pharmaceutical and MACLEODS, etc. AstraZeneca, ANI Pharmaceuticals, TEVA are top 3 players and held % sales share in total in 2022.
Candesartan and Hydrochlorothiazide can be divided into 16/12.5, 32/12.5 and 32/25,, etc. 16/12.5 is the mainstream product in the market, accounting for % sales share globally in 2022.
Candesartan and Hydrochlorothiazide is widely used in various fields, such as Adults and Geriatric, etc. Adults provides greatest supports to the Candesartan and Hydrochlorothiazide industry development. In 2022, global % sales of Candesartan and Hydrochlorothiazide went into Adults filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Candesartan and Hydrochlorothiazide market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
AstraZeneca
ANI Pharmaceuticals
TEVA
Mylan
Dr. Reddy's Laboratories
Zydus Pharmaceuticals
Prinston Pharmaceutical
MACLEODS
Segment by Type
16/12.5
32/12.5
32/25
Segment by Application
Adults
Geriatric
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Candesartan and Hydrochlorothiazide market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Candesartan and Hydrochlorothiazide, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Candesartan and Hydrochlorothiazide industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Candesartan and Hydrochlorothiazide in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Candesartan and Hydrochlorothiazide introduction, etc. Candesartan and Hydrochlorothiazide Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports Conclusions of Candesartan and Hydrochlorothiazide market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices